Table 4.

Adverse events.

	Any grades			⩾ Grades 3
	Child–Pugh B (%)	Child–Pugh A (%)	p-value	Child–Pugh B (%)	Child–Pugh A (%)	p-value
Total	35 (97.2)	118 (88.7)	0.198	16 (44.4)	21 (15.8)	<0.001
Fatigue	15 (41.7)	55 (41.4)	0.973	–	–	–
Pruritus	5 (13.9)	18 (13.5)	0.956	0 (0.0)	2 (1.5)	0.459
Rash	4 (11.1)	19 (14.3)	0.787	0 (0.0)	2 (1.5)	0.459
Anorexia	10 (27.8)	29 (21.8)	0.505	1 (2.8)	2 (1.5)	0.515
Nausea	10 (27.8)	26 (19.5)	0.358	0 (0.0)	1 (0.8)	0.602
Vomiting	2 (5.6)	8 (6.0)	0.917	1 (2.8)	1 (0.8)	0.319
Diarrhea	1 (2.8)	7 (5.3)	0.690	–	–	–
Hypertension	6 (16.7)	72 (54.1)	<0.001	1 (2.8)	6 (4.5)	0.643
Proteinuria	11 (30.6)	48 (36.1)	0.537	0 (0.0)	2 (1.5)	0.459
Pulmonary embolism	0 (0.0)	1 (0.8)	0.602	0 (0.0)	1 (0.8)	0.602
GI perforation	1 (2.8)	2 (1.5)	0.608	1 (2.8)*	2 (1.5)	0.608
GI hemorrhage	6 (16.7)	4 (3.0)	0.002	6 (16.7)	1 (0.8)	<0.001
Hypothyroidism	2 (5.6)	6 (4.6)	0.808	–	–	–
Neutropenia	9 (25.0)	27 (20.3)	0.541	5 (13.9)	0 (0.0)	<0.001
Anemia	12 (33.3)	37 (27.8)	0.518	1 (2.8)	0 (0.0)	0.054
Thrombocytopenia	14 (38.9)	54 (41.2)	0.801	4 (11.1)	1 (0.8)	0.001
AST elevation	20 (55.6)	58 (43.6)	0.202	3 (8.3)	7 (5.3)	0.489
ALT elevation	13 (36.1)	35 (26.3)	0.248	2 (5.6)	1 (0.8)	0.053
Hyperbilirubinemia	23 (63.9)	23 (17.3)	<0.001	2 (5.6)	0 (0.0)	0.006
Dose reduction or interruption	0 (0.0)	4 (3.1)	0.295	–	–	–
Discontinuation	5 (14.3)	12 (9.2)	0.374	–	–	–

ALT, alanine aminotransferase; AST, aspartate aminotransferase; GI, gastrointestinal.

^*Grade 5 toxicity.

Bold statistically significant (p<0.05).